AstraZeneca Licenses Global Rights to Dizal Lung Cancer Drug for Up-to-$1.5B

Dizal has been pursuing approvals from the FDA and China’s Center for Drug Evaluation (CDE) for a new indication for Zegfrovy, as a first-line treatment for NSCLC with exon 20 insertion EGFR…